Aspire Pharma
Aspire Pharma is a UK-based privately held specialty niche generics pharmaceutical company that develops and supplies 400+ enhanced generic medicines across 10 therapy areas to healthcare professionals, hospitals, and national health systems in the UK, Germany, and Ireland.
- Company typePrivate
- Founded2009
- HeadquartersPetersfield, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aspire Pharma does
Aspire Pharma Limited is a privately held UK specialty niche generics pharmaceutical company founded in 2009 and headquartered in Godalming, Surrey. The company's stated operating principle is to take existing medicines, molecules, or devices and enhance them through improved presentation, more convenient dosing, or more acceptable formulations for patients. Its portfolio spans 400+ products across 10 core promotional therapy areas — Anti-Infectives, Cardiology, Dermatology, Gynaecology, Oncology, Metabolism & Endocrinology, Ophthalmology, Urology, Central Nervous System, and Respiratory — sold directly to healthcare professionals, hospitals, and national health systems in the UK, Germany, and Ireland. Aspire generates revenue primarily through one-time product sales of these specialty generics, with pricing negotiated through national health system and hospital procurement channels rather than publicly disclosed.
Aspire is backed by private equity firm HIG Capital, which has supported an aggressive European roll-up acquisition strategy. Between October 2022 and February 2026, Aspire completed at least four acquisitions: Morningside Healthcare (2022), Cenoté Pharma (March 2024), Canute Pharma (October 2024), and Caragen (February 2026). The Caragen deal added Irish distribution rights to over 100 product lines spanning immunology, oncology, infectious diseases, and medical devices, with Caragen retained as an independent operating brand in Ireland. Acquired companies are similarly retained as independent brands, indicating a federation model under a corporate parent rather than full integration.
The company operates through direct sales channels with country-specific websites for the UK (aspirepharma.com) and Germany (aspirepharma.de), supplemented by distributor/wholesale relationships in Ireland via Caragen. It employs 51-100 people, markets to healthcare professionals and national health systems, and positions itself as a value-add alternative to off-patent branded pharmaceuticals across multiple European markets. Richard Condon serves as Chief Executive.
Aspire Pharma firmographics
Firmographics- Name
- Aspire Pharma
- Legal name
- Aspire Pharma Limited
- Website
- https://aspirepharma.co.uk
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Aspire Pharma is a UK-based privately held specialty niche generics pharmaceutical company that develops and supplies 400+ enhanced generic medicines across 10 therapy areas to healthcare professionals, hospitals, and national health systems in the UK, Germany, and Ireland.
- Ownership category
- akta.pro rank
Aspire Pharma industry classification
Industry- Product category
- Specialty Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Oral Solid Dose (OSD) Generics (HLAIABAD)
Keywords
Where Aspire Pharma is headquartered
LocationHeadquarters
- HQ city
- Petersfield
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Aspire Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Generic Pharmaceutical Product Sales: Aspire Pharma generates revenue through the sale of specialty generic pharmaceutical products across 10 therapy areas. The company develops and supplies innovative products and medicines globally, with a portfolio spanning immunology, oncology, infectious diseases, dermatology, cardiology, and other therapeutic categories.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Aspire Pharma product offering
Product offeringCore offering
Aspire Pharma develops, manufactures, and supplies specialty niche generic pharmaceutical products, medical devices, and diagnostics across 10 core therapy areas, with a portfolio of 400+ products. Its founding principle is to enhance existing medicines, molecules, and devices through improved presentation, more convenient dosing, or more acceptable patient formulations. Distribution reaches healthcare professionals, hospitals, and national health systems in the UK, Germany, and Ireland (via the acquired Caragen brand).
Product overview
Aspire Pharma is a UK-based specialty niche generics pharmaceutical company founded in 2009, with a portfolio of 400+ products spanning 10 core promotional therapy areas. The company operates a platform approach across therapeutic areas including Anti-Infectives, Cardiology, Dermatology, Gynaecology, Oncology, Metabolism & Endocrinology, Ophthalmology, Urology, Central Nervous System, and Respiratory. Their product strategy focuses on enhancing existing medicines, molecules, and devices through improved presentation, more convenient dosing, or more acceptable formulations for patients. The company has expanded internationally through multiple acquisitions including Caragen (granting access to 100+ product lines in Ireland across immunology, oncology, infectious diseases, and medical devices), Canute Pharma, and Cenoté Pharma.
Differentiator
Problem solved
Functional benefit
Products and services
- Specialty Niche Generics Pharmaceutical Portfolio A portfolio of 400+ specialty generic pharmaceutical products spanning Anti-Infectives, Cardiology, Dermatology, Gynaecology, Oncology, Metabolism & Endocrinology, Ophthalmology, Urology, Central Nervous System, and Respiratory therapy areas, sold to healthcare professionals, hospitals, and national health systems in the UK, Germany, and Ireland.
- Medical Devices and Hospital Immunology Product Lines (Caragen) Over 100 product lines covering hospital immunology therapies, infectious disease treatments, oncology products, and medical devices, distributed in Ireland through the Caragen brand following acquisition by Aspire Pharma.
Companies that use Aspire Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Aspire Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Aspire Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CaragencoreCaragen is a Dublin-based pharmaceutical organization specializing in hospital immunology therapies and medical devices distribution. Following acquisition by Aspire Pharma, Caragen continues operating as an independent brand in Ireland with its existing management team. The acquisition grants Aspire Irish distribution rights to over 100 product lines spanning immunology, oncology, infectious diseases, and medical devices.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Aspire Pharma competitors and assessment
Company assessmentDirect peers
- Stada Arzneimittel: European-focused generics and specialty pharma with a broad portfolio across multiple therapy areas. Closely comparable to Aspire in its specialty generics positioning, multi-country European footprint, and PE-backed (Cinven/Bain) growth-and-acquisition strategy.
- Zentiva: Pan-European generics manufacturer with broad therapy-area coverage and strong UK/EU retail and hospital presence. Highly comparable to Aspire's portfolio breadth, European geographic mix, and focus on off-patent specialty medicines.
- KRKA: Slovenia-headquartered generics producer with a wide portfolio spanning prescription generics, OTC, and animal health across European and emerging markets. Comparable to Aspire in multi-therapy-area breadth, generics focus, and export-led European growth model.
- Morningside Healthcare: UK specialty generics and consumer health company; the Aspire Pharma predecessor entity acquired in October 2022. Directly comparable as a UK-based specialty generics player with overlapping therapy areas and channel mix.
Broad incumbents
- Teva Pharmaceutical Industries: World's largest generics manufacturer with extensive European presence and a portfolio spanning virtually every therapy area. Comparable to Aspire in generics focus and therapy-area breadth, but operates at much greater scale and competes for the same institutional tenders.
- Sandoz (Novartis): Global generics and biosimilars leader spun out of Novartis. Comparable to Aspire as a European-anchored generics competitor with hospital-channel exposure, though operating at far larger scale across both retail generics and specialty/biosimilars.
- Viatris: Global off-patent pharma company formed from Mylan and Upjohn, with significant European generics presence across multiple therapy areas. Comparable to Aspire in off-patent, multi-therapy-area positioning and hospital/retail channel mix in Europe.
- Almirall: European specialty pharma focused on dermatology and specialty therapeutic areas with strong hospital-channel positioning. Comparable to Aspire's specialty therapy-area emphasis (including dermatology) and European footprint, though Almirall leans toward branded specialty vs. generics.
Regional players
- Polpharma: Central European generics manufacturer with broad prescription generics portfolio across multiple therapy areas. Comparable to Aspire in generics scale and breadth, though primarily Central/Eastern European in geographic focus versus Aspire's UK/Ireland/Germany core.
Emerging players
- Glenmark Pharmaceuticals: India-headquartered specialty generics and branded pharma with growing European presence across dermatology, respiratory, and oncology. Comparable to Aspire in specialty generics positioning and the pursuit of European market entry via targeted product launches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Aspire Pharma social profiles
Digital presenceAspire Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aspire Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Aspire Pharma subsidiaries and ownership
Company hierarchySubsidiaries3 records
Aspire Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aspire Pharma M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aspire Pharma
What does Aspire Pharma do?
Aspire Pharma develops, manufactures, and supplies specialty niche generic pharmaceutical products, medical devices, and diagnostics across 10 core therapy areas, with a portfolio of 400+ products. Its founding principle is to enhance existing medicines, molecules, and devices through improved presentation, more convenient dosing, or more acceptable patient formulations. Distribution reaches healthcare professionals, hospitals, and national health systems in the UK, Germany, and Ireland (via the acquired Caragen brand).
Is Aspire Pharma a public or private company?
Aspire Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was Aspire Pharma founded?
Aspire Pharma was founded in 2009. It employs 101 to 250 people.
Where is Aspire Pharma based?
Aspire Pharma is headquartered in Petersfield, United Kingdom, in the Europe region.
How does Aspire Pharma make money?
One revenue line is on record: generic Pharmaceutical Product Sales.
Who are Aspire Pharma's main competitors?
Direct peers on record are Stada Arzneimittel, Zentiva, KRKA and Morningside Healthcare. Broad incumbents are Teva Pharmaceutical Industries, Sandoz (Novartis), Viatris and Almirall. Polpharma is listed as a regional player. Glenmark Pharmaceuticals is listed as an emerging player.
Does Aspire Pharma have an API?
No public API is recorded for Aspire Pharma.
What industry is Aspire Pharma in?
Aspire Pharma's product category is Specialty Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.